Genomic markers currently used to support decision-making in CRC treatment include the microsatellite instability (MSI) that is associated with lack of efficacy of adjuvant CTX, and KRAS mutations that are predictive of lack of effectiveness of epidermal growth factor receptor (EGFR) inhibitors. Here, EGFR is linked to colorectal carcinoma.